Posts tagged inhalation therapy
Mallinckrodt licenses NeuroproteXeon’s xenon gas therapy

Mallinckrodt (NYSE:MNK) has entered into a licensing agreement for development and commercialization of NeuroproteXeon’s pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and functional outcomes for patients resuscitated after a cardiac arrest.

Read More